[{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chugai Pharmaceutical \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ruzasvir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Atea Pharmaceuticals"}]
Find Clinical Drug Pipeline Developments & Deals for Bemnifosbuvir
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
